ISpecimen Net Income Over Time
| ISPC Stock | USD 0.30 0.02 6.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ISpecimen Performance and ISpecimen Correlation. ISpecimen | Build AI portfolio with ISpecimen Stock |
Will Biotechnology sector continue expanding? Could ISpecimen diversify its offerings? Factors like these will boost the valuation of ISpecimen. Market participants price ISpecimen higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ISpecimen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.82) | Revenue Per Share | Quarterly Revenue Growth (0.96) | Return On Assets | Return On Equity |
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, ISpecimen's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare iSpecimen and related stocks such as ENDRA Life Sciences, Theriva Biologics, and Catheter Precision Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NDRA | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.3 M) | (2.8 M) | (5.4 M) | (9.8 M) | (13.3 M) | (11.7 M) | (11.2 M) | (13.2 M) | (10.1 M) | (11.5 M) | (10.4 M) | (10.9 M) |
| TOVX | (3.9 M) | (8.1 M) | (17.1 M) | (12.3 M) | (19.8 M) | (43.7 M) | (27.3 M) | (15.2 M) | (13.4 M) | (15.3 M) | (10 M) | (14.2 M) | (19.7 M) | (18.3 M) | (25.7 M) | (23.1 M) | (21.9 M) |
| VTAK | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (17.8 M) | (30.8 M) | (57 M) | (36 M) | (25.1 M) | (26.9 M) | (70.6 M) | (16.6 M) | (15 M) | (15.7 M) |
| HSCS | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (2.5 M) | (4.8 M) | (6.4 M) | (6.6 M) | (8.8 M) | (7.9 M) | (8.3 M) |
| GLMD | (3.1 M) | (3.1 M) | (3.1 M) | (17.5 M) | (9.1 M) | (10.6 M) | (17 M) | (12.3 M) | (9.9 M) | (18.5 M) | (27.6 M) | (31.9 M) | (18.6 M) | (6.9 M) | (7.5 M) | (6.8 M) | (7.1 M) |
| BJDX | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (757.7 K) | (1.1 M) | (3.7 M) | (9.3 M) | (10 M) | (7.7 M) | (6.9 M) | (7.3 M) |
| BIVI | (70 K) | (70 K) | (70 K) | (321.9 K) | (233 K) | (431.9 K) | (1.3 M) | (2.4 M) | (2.4 M) | (16.7 M) | (130.2 M) | (26.1 M) | (50.3 M) | (32.1 M) | (17.5 M) | (15.8 M) | (16.6 M) |
| BIAF | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (7.3 M) | (6.3 M) | (8.2 M) | (7.9 M) | (9 M) | (8.1 M) | (8.5 M) |
| SHPH | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (213.6 K) | (626.1 K) | (805.7 K) | (805.7 K) | (1.2 M) | (5 M) | (6.6 M) | (9.1 M) | (8.2 M) | (7.8 M) |
| ZCMD | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 3 M | 4 M | 4.5 M | 238.7 K | (2.9 M) | (11.3 M) | (643.2 K) | (578.9 K) | (550 K) |
iSpecimen and related stocks such as ENDRA Life Sciences, Theriva Biologics, and Catheter Precision Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in iSpecimen financial statement analysis. It represents the amount of money remaining after all of iSpecimen operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| iSpecimen | ISPC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 8 Cabot Road, |
| Exchange | NASDAQ Exchange |
USD 0.3
Check out ISpecimen Performance and ISpecimen Correlation. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
ISpecimen technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.